Return to homepagePandemic Pact

PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS): Bundibugyo virus disease therapeutics trial

  • Funded by Foreign, Commonwealth & Development Office (FCDO)
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    Ebola

  • Start & end year

    2026

  • Known Financial Commitments (USD)

    $2,693,000

  • Funder

    Foreign, Commonwealth & Development Office (FCDO)

  • Principal Investigator

    Professor Amanda Rojek

  • Research Location

    Congo (DRC)

  • Lead Research Institution

    University of Oxford

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Emergency clinical trial evaluating potential treatments for Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo. The adaptive platform initially evaluates MBP134 and remdesivir, alone or in combination. International coordination is led by the Pandemic Sciences Institute at the University of Oxford; WHO sponsors the trial and national and international partners deliver it in the DRC.